K. Adalet et al., THE EFFECT OF AMLODIPINE ON THE MASS AND FUNCTION OF THE LEFT-VENTRICLE IN PATIENTS WITH PRIMARY HYPERTENSION AND LEFT-VENTRICULAR HYPERTROPHY, Current therapeutic research, 56(6), 1995, pp. 607-616
Citations number
33
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
The aim of this study was to assess the effects of amlodipine in patie
nts with mild-to-moderate primary hypertension and left ventricular hy
pertrophy. Nineteen patients (6 women, 13 men; mean age, 52 years) wit
h primary hypertension were included in the study and all completed th
e study. After the 2-week, single-blind placebo phase, 5 mg/d oral aml
odipine was initiated. If diastolic blood pressure (DBP) could not be
reduced below the target level (less than or equal to 90 mm Hg) after
6 weeks of treatment, the dose of amlodipine was increased to 10 mg/d.
Clinical evaluation was performed at weeks 0, 1, 2, 4, 6, 8, 10, 14,
18, 22, and 26, and echocardiography at the end of the placebo phase a
nd at weeks 14 and 26. No significant reduction in blood pressure was
recorded during the placebo phase. Systolic and diastolic blood pressu
res (mean +/- SE) were 163 +/- 20 mm Hg and 102 +/- 5.4 mm Hg, respect
ively, at the end of the placebo phase; these values were reduced to 1
39 +/- 19 mm Hg (P < 0.001) and 86 +/- 8 mm Hg (P < 0.001) at week 14.
This reduction in blood pressure was maintained until the end of the
study. No significant alterations were shown in heart rate during the
study. DBP was reduced to less than or equal to 90 mm Hg in 10 (53%) o
f 19 patients with 5 mg/d and in 6 (32%) of 19 patients with 10 mg/d o
f amlodipine. Thus an overall therapeutic success of 84% was achieved.
Left ventricular mass index (mean +/- SE) was 147 +/- 20 g/m(2) at th
e end of the placebo phase; it decreased to 129 +/- 20 g/m(2) at week
14 (P < 0.001) and to 123 +/- 19 g/m(2) at week 26 (P < 0.05 for the v
alues at weeks 14 and 26). The mitral early filling flow velocity (wav
e E) to late filling flow velocity (wave A) ratio was significantly in
creased 0.7 +/- 0.1 to 0.9 +/- 0.2 at the end of the trial (P < 0.001)
. Echocardiographic assessment showed no statistically significant cha
nges in left ventricular ejection fraction and cardiac index. It was c
oncluded that amlodipine, given in single daily doses, is an effective
antihypertensive agent in patients with primary hypertension, improvi
ng left ventricular diastolic function and reducing left ventricular h
ypertrophy.